LON:AGY - Allergy Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 25.80 -0.70 (-2.64 %)
(As of 05/24/2018 09:57 AM ET)
Previous CloseGBX 26.50
Today's RangeGBX 25.58 - GBX 26.02
52-Week RangeGBX 23 - GBX 39.50
Volume83,412 shs
Average Volume167,682 shs
Market Capitalization£144.63 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Allergy Therapeutics (LON:AGY)

Allergy Therapeutics logoAllergy Therapeutics plc, a specialty pharmaceutical company, focuses on allergy vaccination primarily in Europe. The company's primary flagship product is the Pollinex Quattro for the treatment of allergic conditions. It offers monophosphoryl-lipid A, a substance that enhances the immune response to an antigen or allergen; sublingual product, including Oralvac Compact; Venomil product, which is used for the wasp and bee treatment; and synbiotics that are special formulations of prebiotics and probiotics, such as Kallergen-Th, ATI Prob, and Pollagen. The company also provides Acarovac Plus, a novel microcrystalline tyrosine adsorbed, modified-allergen product developed for treatment of perennial mite allergy; and DAP, a product for use in the diagnosis of type I or immediate hypersensitivity to benzyl penicillin and related antibiotics (beta lactams) by means of cutaneous tests (prick and intradermal). In addition, it develops products based on synbiotics that are Kallergen Th and SynGut; Acarovac Plus and Acarovac MPL that are next generation products for dust mite immunotherapy; Polyvac, a peanut vaccine; and G204, G205, and G306, as well as PQBirch 301 and PQBirch 204 that are subcutaneous immunotherapies, which are in various development phases. The company markets its products in injectable and sublingual formats under various brands. Allergy Therapeutics plc was founded in 1934 and is based in Worthing, the United Kingdom.

Receive AGY News and Ratings via Email

Sign-up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
SymbolLON:AGY
CUSIPN/A
Phone+44-1903-844700

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins14.27%
Return on Equity36.50%
Return on Assets19.69%

Miscellaneous

EmployeesN/A
Outstanding Shares603,970,000

Allergy Therapeutics (LON:AGY) Frequently Asked Questions

What is Allergy Therapeutics' stock symbol?

Allergy Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "AGY."

What price target have analysts set for AGY?

2 analysts have issued twelve-month target prices for Allergy Therapeutics' stock. Their predictions range from GBX 45 to GBX 47. On average, they anticipate Allergy Therapeutics' share price to reach GBX 46 in the next year. View Analyst Ratings for Allergy Therapeutics.

Who are some of Allergy Therapeutics' key competitors?

Who are Allergy Therapeutics' key executives?

Allergy Therapeutics' management team includes the folowing people:
  • Mr. Manuel Llobet, CEO & Exec. Director (Age 54)
  • Mr. Nicolas Alexander Ulrich Wykeman, Fin. Director & Exec. Director (Age 53)
  • Ms. Beverly Lees, Operations Director
  • Dr. Murray Skinner, Chief Scientific Officer
  • Mr. Santiago Puig, Bus. Devel. Director

Has Allergy Therapeutics been receiving favorable news coverage?

News articles about AGY stock have trended positive on Thursday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Allergy Therapeutics earned a media sentiment score of 0.25 on Accern's scale. They also assigned media headlines about the company an impact score of 45.24 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of Allergy Therapeutics?

Shares of AGY and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Allergy Therapeutics' stock price today?

One share of AGY stock can currently be purchased for approximately GBX 25.80.

How big of a company is Allergy Therapeutics?

Allergy Therapeutics has a market capitalization of £144.63 million.

How can I contact Allergy Therapeutics?

Allergy Therapeutics' mailing address is Dominion Way, WORTHING, BN14 8SA, United Kingdom. The company can be reached via phone at +44-1903-844700.


MarketBeat Community Rating for Allergy Therapeutics (AGY)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  263 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  362
MarketBeat's community ratings are surveys of what our community members think about Allergy Therapeutics and other stocks. Vote "Outperform" if you believe AGY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Allergy Therapeutics (LON:AGY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Allergy Therapeutics in the last 12 months. Their average twelve-month price target is GBX 46The high price target for AGY is GBX 47 and the low price target for AGY is GBX 45. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 46GBX 46GBX 51.25GBX 51.25

Allergy Therapeutics (LON:AGY) Consensus Price Target History

Price Target History for Allergy Therapeutics (LON:AGY)

Allergy Therapeutics (LON:AGY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/21/2018Numis SecuritiesReiterated RatingBuyView Rating Details
5/21/2018FinnCapReiterated RatingCorporateView Rating Details
9/28/2017Panmure GordonReiterated RatingBuyView Rating Details
4/4/2017Stifel NicolausReiterated RatingBuyGBX 60View Rating Details
(Data available from 5/24/2016 forward)

Earnings

Dividends

Allergy Therapeutics (LON:AGY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Allergy Therapeutics (LON AGY) Insider Trading and Institutional Ownership History

Insider Trading History for Allergy Therapeutics (LON:AGY)

Allergy Therapeutics (LON AGY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/11/2017Tunde OtulanaInsiderBuy25,000GBX 51£12,750
9/29/2016Peter JensenInsiderBuy30,000GBX 19£5,700
9/27/2016Nicolas WykemanInsiderBuy150,000GBX 18£27,000
7/27/2015Llobet ,ManuelInsiderBuy50,000GBX 24£12,000
(Data available from 1/1/2013 forward)

Headlines

Allergy Therapeutics (LON AGY) News Headlines

Source:
DateHeadline
Allergy Therapeutics (AGY) Stock Rating Reaffirmed by FinnCapAllergy Therapeutics (AGY) Stock Rating Reaffirmed by FinnCap
www.americanbankingnews.com - May 21 at 10:00 AM
Allergy Therapeutics (AGY) Given Buy Rating at Numis SecuritiesAllergy Therapeutics (AGY) Given Buy Rating at Numis Securities
www.americanbankingnews.com - May 21 at 10:00 AM
Hardman & Co Research: Allergy Therapeutics (AGY): Opening the door to registrationHardman & Co Research: Allergy Therapeutics (AGY): Opening the door to registration
www.finanznachrichten.de - May 21 at 9:16 AM
Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging studyAllergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study
globenewswire.com - May 21 at 9:16 AM
Has Allergy Therapeutics plc (LON:AGY) Improved Earnings Growth In Recent Times?Has Allergy Therapeutics plc (LON:AGY) Improved Earnings Growth In Recent Times?
finance.yahoo.com - May 17 at 9:44 AM
FinnCap Increases Allergy Therapeutics (AGY) Price Target to GBX 46FinnCap Increases Allergy Therapeutics (AGY) Price Target to GBX 46
www.americanbankingnews.com - April 17 at 9:15 PM
Allergy Therapeutics (AGY) "Buy" Rating Reiterated at Numis SecuritiesAllergy Therapeutics' (AGY) "Buy" Rating Reiterated at Numis Securities
www.americanbankingnews.com - April 17 at 7:34 PM
Panmure Gordon Reaffirms "Buy" Rating for Allergy Therapeutics (AGY)Panmure Gordon Reaffirms "Buy" Rating for Allergy Therapeutics (AGY)
www.americanbankingnews.com - April 8 at 9:42 PM
Allergy Therapeutics (AGY) Buy Rating Reaffirmed at Numis SecuritiesAllergy Therapeutics' (AGY) Buy Rating Reaffirmed at Numis Securities
www.americanbankingnews.com - March 26 at 10:53 AM
Allergy Therapeutics (AGY) Earns "Corporate" Rating from FinnCapAllergy Therapeutics (AGY) Earns "Corporate" Rating from FinnCap
www.americanbankingnews.com - March 25 at 9:48 PM
Allergy Therapeutics (AGY) Given Corporate Rating at FinnCapAllergy Therapeutics (AGY) Given Corporate Rating at FinnCap
www.americanbankingnews.com - March 24 at 6:46 PM
FinnCap Reiterates Corporate Rating for Allergy Therapeutics (AGY)FinnCap Reiterates Corporate Rating for Allergy Therapeutics (AGY)
www.americanbankingnews.com - March 24 at 11:20 AM
Allergy Therapeutics (AGY) Receives Buy Rating from Numis SecuritiesAllergy Therapeutics (AGY) Receives Buy Rating from Numis Securities
www.americanbankingnews.com - March 7 at 4:44 PM
Allergy Therapeutics (AGY) "Corporate" Rating Reaffirmed at FinnCapAllergy Therapeutics' (AGY) "Corporate" Rating Reaffirmed at FinnCap
www.americanbankingnews.com - February 19 at 5:52 PM
Allergy Therapeutics (AGY) Buy Rating Reiterated at Numis SecuritiesAllergy Therapeutics' (AGY) Buy Rating Reiterated at Numis Securities
www.americanbankingnews.com - December 10 at 8:06 PM
Allergy Therapeutics to Present at Jefferies 2017 - London South East (blog)Allergy Therapeutics to Present at Jefferies 2017 - London South East (blog)
www.lse.co.uk - November 14 at 4:23 AM
Allergy Therapeutics Plc breached its 50 day moving average in a Bearish Manner : AGY-GB : November 10, 2017Allergy Therapeutics Plc breached its 50 day moving average in a Bearish Manner : AGY-GB : November 10, 2017
finance.yahoo.com - November 10 at 2:37 PM
Allergy Therapeutics Plc :AGY-GB: Earnings Analysis: For the six months ended June 30, 2017 : November 2, 2017Allergy Therapeutics Plc :AGY-GB: Earnings Analysis: For the six months ended June 30, 2017 : November 2, 2017
finance.yahoo.com - November 2 at 9:02 PM
Allergy Therapeutics Plc :AGY-GB: Earnings Analysis: 2017 By the Numbers : October 24, 2017Allergy Therapeutics Plc :AGY-GB: Earnings Analysis: 2017 By the Numbers : October 24, 2017
finance.yahoo.com - October 24 at 9:35 PM
Allergy Thera. Share ChatAllergy Thera. Share Chat
www.lse.co.uk - October 24 at 2:48 AM
Allergy Therapeutics plc (AGY) Rating Reiterated by FinnCapAllergy Therapeutics plc (AGY) Rating Reiterated by FinnCap
www.americanbankingnews.com - October 21 at 9:58 PM
Allergy Therapeutics plc (AGY) Insider Acquires £12,750 in StockAllergy Therapeutics plc (AGY) Insider Acquires £12,750 in Stock
www.americanbankingnews.com - October 12 at 1:22 PM
Allergy Therapeutics Plc breached its 50 day moving average in a Bearish Manner : AGY-GB : November 24, 2016Allergy Therapeutics Plc breached its 50 day moving average in a Bearish Manner : AGY-GB : November 24, 2016
finance.yahoo.com - October 5 at 12:59 PM
Allergy Therapeutics Plc breached its 50 day moving average in a Bullish Manner : AGY-GB : January 9, 2017Allergy Therapeutics Plc breached its 50 day moving average in a Bullish Manner : AGY-GB : January 9, 2017
finance.yahoo.com - October 5 at 12:59 PM
Allergy Therapeutics Plc – Value Analysis (LONDON:AGY) : January 10, 2017Allergy Therapeutics Plc – Value Analysis (LONDON:AGY) : January 10, 2017
finance.yahoo.com - October 5 at 12:59 PM
Allergy Therapeutics: Positive Efficacy and Safety Data Shown in Peanut Allergy VaccineAllergy Therapeutics: Positive Efficacy and Safety Data Shown in Peanut Allergy Vaccine
finance.yahoo.com - October 5 at 12:59 PM
Allergy Therapeutics Plc breached its 50 day moving average in a Bearish Manner : AGY-GB : March 23, 2017Allergy Therapeutics Plc breached its 50 day moving average in a Bearish Manner : AGY-GB : March 23, 2017
finance.yahoo.com - October 5 at 12:59 PM
Allergy Therapeutics Plc breached its 50 day moving average in a Bearish Manner : AGY-GB : May 5, 2017Allergy Therapeutics Plc breached its 50 day moving average in a Bearish Manner : AGY-GB : May 5, 2017
finance.yahoo.com - October 5 at 12:58 PM
Allergy Therapeutics Plc – Value Analysis (LONDON:AGY) : May 8, 2017Allergy Therapeutics Plc – Value Analysis (LONDON:AGY) : May 8, 2017
finance.yahoo.com - October 5 at 12:58 PM
Allergy Therapeutics Plc :AGY-GB: Earnings Analysis: For the six months ended December 31, 2016 : May 12, 2017Allergy Therapeutics Plc :AGY-GB: Earnings Analysis: For the six months ended December 31, 2016 : May 12, 2017
finance.yahoo.com - October 5 at 12:58 PM
Allergy Therapeutics Plc breached its 50 day moving average in a Bullish Manner : AGY-GB : May 18, 2017Allergy Therapeutics Plc breached its 50 day moving average in a Bullish Manner : AGY-GB : May 18, 2017
finance.yahoo.com - October 5 at 12:58 PM
FinnCap Increases Allergy Therapeutics plc (AGY) Price Target to GBX 47FinnCap Increases Allergy Therapeutics plc (AGY) Price Target to GBX 47
www.americanbankingnews.com - September 30 at 4:08 PM
Allergy Therapeutics plc (AGY) Stock Rating Reaffirmed by Numis Securities LtdAllergy Therapeutics plc (AGY) Stock Rating Reaffirmed by Numis Securities Ltd
www.americanbankingnews.com - September 30 at 3:28 PM
Allergy Therapeutics plc (AGY) Given Buy Rating at Panmure GordonAllergy Therapeutics plc (AGY) Given Buy Rating at Panmure Gordon
www.americanbankingnews.com - September 30 at 2:54 PM
Allergy Therapeutics: Preliminary ResultsAllergy Therapeutics: Preliminary Results
globenewswire.com - September 28 at 4:15 PM
Allergy Therapeutics plc (AGY) Rating Reiterated by Numis Securities LtdAllergy Therapeutics plc (AGY) Rating Reiterated by Numis Securities Ltd
www.americanbankingnews.com - September 22 at 9:02 PM
Allergy Therapeutics plc (AGY) Stock Rating Reaffirmed by FinnCapAllergy Therapeutics plc (AGY) Stock Rating Reaffirmed by FinnCap
www.americanbankingnews.com - August 28 at 5:02 PM
Half Year 2017 Allergy Therapeutics PLC Earnings Release - Before Market OpenHalf Year 2017 Allergy Therapeutics PLC Earnings Release - Before Market Open
biz.yahoo.com - March 9 at 3:28 PM
DGAP-News: Bencard Allergie GmbH: Update zur ... - FinanzNachrichten.deDGAP-News: Bencard Allergie GmbH: Update zur ... - FinanzNachrichten.de
www.finanznachrichten.de - January 19 at 3:42 PM
Secretive Biotech Unicorn Moderna Unveils Pipeline, Financials - BloombergSecretive Biotech Unicorn Moderna Unveils Pipeline, Financials - Bloomberg
www.bloomberg.com - January 10 at 1:41 AM
Ultragenyx and Kyowa Kirin International Announce Marketing Authorization Application for KRN23 Filed and Accepted ... - GlobeNewswire (press release)Ultragenyx and Kyowa Kirin International Announce Marketing Authorization Application for KRN23 Filed and Accepted ... - GlobeNewswire (press release)
globenewswire.com - January 5 at 8:32 PM
Do today’s results make this company a better buy than Shire plc?Do today’s results make this company a better buy than Shire plc?
uk.finance.yahoo.com - September 26 at 9:32 AM
Full Year 2016 Allergy Therapeutics PLC Earnings Release - Before Market OpenFull Year 2016 Allergy Therapeutics PLC Earnings Release - Before Market Open
biz.yahoo.com - September 26 at 9:32 AM

SEC Filings

Allergy Therapeutics (LON:AGY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Allergy Therapeutics (LON AGY) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.